-
1دورية أكاديمية
المؤلفون: de Matos Simoes R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Shirasaki R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Downey-Kopyscinski SL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Matthews GM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Barwick BG; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Gupta VA; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Dupéré-Richer D; University of Florida Health Cancer Center, Gainesville, FL, USA., Yamano S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Hu Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sheffer M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Dhimolea E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Dashevsky O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Gandolfi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Ishiguro K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Meyers RM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Bryan JG; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dharia NV; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hengeveld PJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Brüggenthies JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Tang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Sievers QL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Glassner BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Ott CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Kwiatkowski NP; Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Levy J; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Keats JJ; Translational Genomics Research Institute, Phoenix, AZ, USA., Groen RWJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Gray NS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Culhane AC; Department of Data Sciences, Dana-Farber Cancer Institute & Harvard School of Public Health, Boston, MA, USA.; Limerick Digital Cancer Research Center, Health Research Institute, School of Medicine, University of Limerick, Limerick, Ireland., McFarland JM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dempster JM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Licht JD; University of Florida Health Cancer Center, Gainesville, FL, USA., Boise LH; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Vazquez F; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. vazquez@broadinstitute.org., Tsherniak A; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. aviad@broadinstitute.org., Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Ludwig Center at Harvard, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.
المصدر: Nature cancer [Nat Cancer] 2023 May; Vol. 4 (5), pp. 754-773. Date of Electronic Publication: 2023 May 26.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
مواضيع طبية MeSH: Multiple Myeloma*/genetics, Humans ; Genomics ; Genome ; Clustered Regularly Interspaced Short Palindromic Repeats/genetics
-
2دورية أكاديمية
المؤلفون: Jan M; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA., Scarfò I; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Larson RC; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Walker A; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA., Schmidts A; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Guirguis AA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gasser JA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Słabicki M; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Bouffard AA; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Castano AP; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Kann MC; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Cabral ML; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Tepper A; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Grinshpun DE; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Sperling AS; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Kyung T; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA., Sievers QL; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Birnbaum ME; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA., Maus MV; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. mvmaus@mgh.harvard.edu benjamin_ebert@dfci.harvard.edu.; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Ebert BL; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. mvmaus@mgh.harvard.edu benjamin_ebert@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
المصدر: Science translational medicine [Sci Transl Med] 2021 Jan 06; Vol. 13 (575).
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE
مواضيع طبية MeSH: Lenalidomide* , Receptors, Chimeric Antigen* , T-Lymphocytes*, Humans ; Jurkat Cells ; Receptors, Antigen, T-Cell ; Ubiquitin-Protein Ligases
-
3دورية أكاديمية
المؤلفون: Shirasaki R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Matthews GM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Gandolfi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., de Matos Simoes R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Buckley DL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Raja Vora J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sievers QL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Brüggenthies JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Dashevsky O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Poarch H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Bariteau MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sheffer M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Hu Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Downey-Kopyscinski SL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hengeveld PJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Glassner BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Dhimolea E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Ott CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Zhang T; Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Kwiatkowski NP; Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Laubach JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Schlossman RL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Culhane AC; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA., Groen RWJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Fischer ES; Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Vazquez F; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Tsherniak A; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Levy J; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Licht JD; University of Florida Health Cancer Center, Gainesville, FL, USA., Keats JJ; Translational Genomics Research Institute, Phoenix, AZ, USA., Boise LH; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Gray NS; Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: constantine_mitsiades@dfci.harvard.edu.
المصدر: Cell reports [Cell Rep] 2021 Jan 05; Vol. 34 (1), pp. 108532.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE
مواضيع طبية MeSH: Adaptor Proteins, Signal Transducing/*metabolism , Antineoplastic Agents/*pharmacology , Multiple Myeloma/*genetics , Multiple Myeloma/*metabolism , Ubiquitin-Protein Ligases/*metabolism , Von Hippel-Lindau Tumor Suppressor Protein/*metabolism, Animals ; CRISPR-Cas Systems ; Cell Line, Tumor ; Cyclin-Dependent Kinase 9/metabolism ; Drug Resistance, Neoplasm ; Gene Editing ; Gene Expression Regulation, Neoplastic ; Genes, Overlapping ; Genome-Wide Association Study ; Genomics/methods ; Humans ; Mice ; Multiple Myeloma/drug therapy ; Oncogene Proteins/metabolism ; Proteins/antagonists & inhibitors ; Proteins/metabolism ; Proteolysis ; Tumor Cells, Cultured
-
4دورية أكاديمية
المؤلفون: Słabicki M; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany., Kozicka Z; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.; Faculty of Science, University of Basel, Basel, Switzerland., Petzold G; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Li YD; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA., Manojkumar M; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany., Bunker RD; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.; Monte Rosa Therapeutics, Basel, Switzerland., Donovan KA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Sievers QL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Koeppel J; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany., Suchyta D; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.; Faculty of Science, University of Basel, Basel, Switzerland., Sperling AS; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fink EC; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gasser JA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wang LR; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Corsello SM; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sellar RS; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Haematology, UCL Cancer Institute, University College London, London, UK., Jan M; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gillingham D; Faculty of Science, University of Basel, Basel, Switzerland., Scholl C; Division of Applied Functional Genomics, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany., Fröhling S; Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.; German Cancer Consortium, Heidelberg, Germany., Golub TR; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Howard Hughes Medical Institute, Boston, MA, USA., Fischer ES; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Thomä NH; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. nicolas.thoma@fmi.ch., Ebert BL; Broad Institute of MIT and Harvard, Cambridge, MA, USA. benjamin_ebert@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. benjamin_ebert@dfci.harvard.edu.; Howard Hughes Medical Institute, Boston, MA, USA. benjamin_ebert@dfci.harvard.edu.
المصدر: Nature [Nature] 2020 Sep; Vol. 585 (7824), pp. 293-297. Date of Electronic Publication: 2020 Jun 03.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
مواضيع طبية MeSH: Cyclins/*deficiency , Cyclins/*metabolism , Proteolysis/*drug effects , Purines/*chemistry , Purines/*pharmacology , Pyridines/*chemistry , Pyridines/*pharmacology, Cell Line, Tumor ; Cyclin-Dependent Kinases/antagonists & inhibitors ; Cyclin-Dependent Kinases/chemistry ; Cyclin-Dependent Kinases/metabolism ; Cyclins/chemistry ; DNA-Binding Proteins/metabolism ; Humans ; Models, Molecular ; Proteasome Endopeptidase Complex/metabolism ; Protein Binding/drug effects ; Purines/toxicity ; Pyridines/toxicity ; Small Molecule Libraries/analysis ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/pharmacology ; Ubiquitination/drug effects
-
5دورية أكاديمية
المؤلفون: Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Burgess M; Broad Institute of MIT and Harvard, Cambridge, MA., Keshishian H; Broad Institute of MIT and Harvard, Cambridge, MA., Gasser JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Bhatt S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jan M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Słabicki M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Division of Translational Oncology, National Center for Tumor Diseases Heidelberg, German Cancer Research Center, Heidelberg, Germany; and., Sellar RS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom., Fink EC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Miller PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Liddicoat BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Sievers QL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Sharma R; Division of Hematology, Brigham and Women's Hospital, Boston, MA., Adams DN; Division of Hematology, Brigham and Women's Hospital, Boston, MA., Olesinski EA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Udeshi ND; Broad Institute of MIT and Harvard, Cambridge, MA., Kuhn E; Broad Institute of MIT and Harvard, Cambridge, MA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Carr SA; Broad Institute of MIT and Harvard, Cambridge, MA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.
المصدر: Blood [Blood] 2019 Jul 11; Vol. 134 (2), pp. 160-170. Date of Electronic Publication: 2019 May 01.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
مواضيع طبية MeSH: Proteolysis/*drug effects , Thalidomide/*analogs & derivatives , Thalidomide/*chemistry , Thalidomide/*pharmacology , Ubiquitin-Protein Ligases/*chemistry, Hematologic Neoplasms/enzymology ; Humans ; Substrate Specificity ; Ubiquitin-Protein Ligases/drug effects
-
6دورية أكاديمية
المؤلفون: Sievers QL; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Brigham and Women's Hospital, Division of Hematology, Harvard Medical School, Boston, MA 02115, USA., Petzold G; Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland., Bunker RD; Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland., Renneville A; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Brigham and Women's Hospital, Division of Hematology, Harvard Medical School, Boston, MA 02115, USA., Słabicki M; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Brigham and Women's Hospital, Division of Hematology, Harvard Medical School, Boston, MA 02115, USA.; Division of Translational Oncology, National Center for Tumor Diseases, Heidelberg and German Cancer Research Center, 69120 Heidelberg, Germany., Liddicoat BJ; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Brigham and Women's Hospital, Division of Hematology, Harvard Medical School, Boston, MA 02115, USA., Abdulrahman W; Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland., Mikkelsen T; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Ebert BL; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. benajmin_ebert@dfci.harvard.edu nicolas.thoma@fmi.ch.; Brigham and Women's Hospital, Division of Hematology, Harvard Medical School, Boston, MA 02115, USA.; Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02215, USA., Thomä NH; Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland. benajmin_ebert@dfci.harvard.edu nicolas.thoma@fmi.ch.
المصدر: Science (New York, N.Y.) [Science] 2018 Nov 02; Vol. 362 (6414).
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE
مواضيع طبية MeSH: CYS2-HIS2 Zinc Fingers*, Lenalidomide/*pharmacology , Peptide Hydrolases/*metabolism , Proteolysis/*drug effects , Thalidomide/*analogs & derivatives , Ubiquitin-Protein Ligases/*metabolism , Ubiquitination/*drug effects, Adaptor Proteins, Signal Transducing ; Amino Acid Sequence ; HEK293 Cells ; Humans ; Ikaros Transcription Factor/metabolism ; Proteome/metabolism ; Thalidomide/pharmacology
-
7دورية أكاديمية
المؤلفون: Sievers QL; Broad Institute of MIT and Harvard, Cambridge, MA.; Division of Hematology, Brigham and Women's Hospital, and.; MD/PhD Program, Harvard Medical School, Boston, MA., Gasser JA; Broad Institute of MIT and Harvard, Cambridge, MA.; Division of Hematology, Brigham and Women's Hospital, and., Cowley GS; Broad Institute of MIT and Harvard, Cambridge, MA., Fischer ES; Department of Chemical Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; and., Ebert BL; Broad Institute of MIT and Harvard, Cambridge, MA.; Division of Hematology, Brigham and Women's Hospital, and.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
المصدر: Blood [Blood] 2018 Sep 20; Vol. 132 (12), pp. 1293-1303. Date of Electronic Publication: 2018 Jul 24.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood
مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Lenalidomide/*pharmacology , Multiple Myeloma/*drug therapy , Ubiquitin-Protein Ligases/*metabolism, CRISPR-Cas Systems ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Humans ; Multiple Myeloma/genetics ; Multiple Myeloma/metabolism ; Ubiquitin-Conjugating Enzymes/metabolism ; Ubiquitin-Protein Ligases/genetics ; Ubiquitination/drug effects
-
8دورية أكاديمية
المؤلفون: Tothova Z; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Krill-Burger JM; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Popova KD; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Landers CC; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Sievers QL; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA., Yudovich D; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Belizaire R; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Aster JC; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Morgan EA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Tsherniak A; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Ebert BL; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: bebert@partners.org.
المصدر: Cell stem cell [Cell Stem Cell] 2017 Oct 05; Vol. 21 (4), pp. 547-555.e8.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101311472 Publication Model: Print Cited Medium: Internet ISSN: 1875-9777 (Electronic) Linking ISSN: 18759777 NLM ISO Abbreviation: Cell Stem Cell Subsets: MEDLINE
مواضيع طبية MeSH: Gene Editing* , Genome, Human* , Hematopoiesis* , Models, Biological*, CRISPR-Cas Systems/*genetics , Hematopoietic Stem Cells/*metabolism , Myeloproliferative Disorders/*genetics , Myeloproliferative Disorders/*pathology, Animals ; Antigens, CD34/metabolism ; Cell Lineage ; Clone Cells ; Genotype ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia/pathology ; Mice ; Mutation/genetics ; Zygote/metabolism
-
9دورية أكاديمية
المؤلفون: Wang L; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;, Shalek AK; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;, Lawrence M; Broad Institute, Cambridge, MA;, Ding R; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;, Gaublomme JT; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;, Pochet N; Broad Institute, Cambridge, MA;, Stojanov P; Broad Institute, Cambridge, MA;, Sougnez C; Broad Institute, Cambridge, MA;, Shukla SA; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;, Stevenson KE; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;, Zhang W; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;, Wong J; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;, Sievers QL; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;, MacDonald BT; F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA; Department of Neurology, Harvard Medical School, Boston, MA;, Vartanov AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;, Goldstein NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;, Neuberg D; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;, He X; F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA; Department of Neurology, Harvard Medical School, Boston, MA;, Lander E; Broad Institute, Cambridge, MA;, Hacohen N; Broad Institute, Cambridge, MA; Division of Allergy, Immunology and Rheumatology, Department of Medicine, Massachusetts General Hospital, Boston MA; and., Regev A; Broad Institute, Cambridge, MA;, Getz G; Broad Institute, Cambridge, MA;, Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Park H; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;, Wu CJ; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
المصدر: Blood [Blood] 2014 Aug 14; Vol. 124 (7), pp. 1089-98. Date of Electronic Publication: 2014 Apr 28.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
مواضيع طبية MeSH: Mutation*, Leukemia, Lymphocytic, Chronic, B-Cell/*genetics , Signal Transduction/*genetics , Wnt Signaling Pathway/*genetics , beta Catenin/*metabolism, Adult ; Cell Line, Tumor ; Cell Survival/genetics ; Cells, Cultured ; Gene Expression Profiling ; Gene Expression Regulation, Leukemic ; HEK293 Cells ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Oligonucleotide Array Sequence Analysis ; RNA Interference ; Reverse Transcriptase Polymerase Chain Reaction
-
10دورية أكاديمية
المؤلفون: Burkhardt UE; Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA., Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ
المصدر: The Journal of clinical investigation [J Clin Invest] 2013 Sep; Vol. 123 (9), pp. 3756-65. Date of Electronic Publication: 2013 Aug 05.
نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
مواضيع طبية MeSH: Cancer Vaccines* , Hematopoietic Stem Cell Transplantation*, CD8-Positive T-Lymphocytes/*immunology , Leukemia, Lymphocytic, Chronic, B-Cell/*therapy, Adult ; Aged ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Granulocyte-Macrophage Colony-Stimulating Factor/metabolism ; Humans ; K562 Cells ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Prospective Studies ; Transplantation Conditioning ; Transplantation, Autologous ; Treatment Outcome ; Vaccination